- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 570909, 8 pages
ISG15 Inhibits IFN-α-Resistant Liver Cancer Cell Growth
1Department of Biochemistry, School of Life Sciences, Central South University, Changsha, Hunan 410013, China
2Department of Biochemistry/Molecular Biology, Philadelphia College of Osteopathic Medicine, Philadelphia, PA 19131, USA
Received 1 April 2013; Revised 2 July 2013; Accepted 2 July 2013
Academic Editor: John N. Plevris
Copyright © 2013 Xin-xing Wan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- R. G. Gish, “Hepatocellular carcinoma: overcoming challenges in disease management,” Clinical Gastroenterology and Hepatology, vol. 4, no. 3, pp. 252–261, 2006.
- M. A. Worns and P. R. Galle, “Future perspectives in hepatocellular carcinoma,” Digestive and Liver Disease, vol. 42, supplement 3, pp. S302–S309, 2010.
- J. N. Ihle, “The Janus protein tyrosine kinase family and its role in cytokine signaling,” Advances in Immunology, vol. 60, pp. 1–35, 1995.
- S. Hervas-Stubbs, J. L. Perez-Gracia, A. Rouzaut, M. F. Sanmamed, A. Le Bon, and I. Melero, “Direct effects of type I interferons on cells of the immune system,” Clinical Cancer Research, vol. 17, no. 9, pp. 2619–2627, 2011.
- J. J. Ghislain, T. Wong, M. Nguyen, and E. N. Fish, “The interferon-inducible Stat2:Stat1 heterodimer preferentially binds in vitro to a consensus element found in the promoters of a subset of interferon-stimulated genes,” Journal of Interferon and Cytokine Research, vol. 21, no. 6, pp. 379–388, 2001.
- E. Knigth Jr., D. Fahey, B. Cordova et al., “A 15-kDa interferon-induced protein is derived by COOH-terminal processing of a 17-kDa precursor,” The Journal of Biological Chemistry, vol. 263, no. 10, pp. 4520–4522, 1988.
- C. M. Pickart and D. Fushman, “Polyubiquitin chains: polymeric protein signals,” Current Opinion in Chemical Biology, vol. 8, no. 6, pp. 610–616, 2004.
- A. Hershko and A. Ciechanover, “The ubiquitin system,” Annual Review of Biochemistry, vol. 67, pp. 425–479, 1998.
- W. Yuan and R. M. Krug, “Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein,” EMBO Journal, vol. 20, no. 3, pp. 362–371, 2001.
- W. Zou and D.-E. Zhang, “The interferon-inducible ubiquitin-protein isopeptide ligase (E3) EFP also functions as an ISG15 E3 ligase,” The Journal of Biological Chemistry, vol. 281, no. 7, pp. 3989–3994, 2006.
- C. Zhao, S. L. Beaudenon, M. L. Kelley et al., “The UbcH8 ubiquitin E2 enzyme is also the E2 enzyme for ISG15, an IFN-α/β-induced ubiquitin-like protein,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 20, pp. 7578–7582, 2004.
- S. D. Desai, L. M. Wood, Y.-C. Tsai et al., “ISG15 as a novel tumor biomarker for drug sensitivity,” Molecular Cancer Therapeutics, vol. 7, no. 6, pp. 1430–1439, 2008.
- C. M. Vollmer, A. Ribas, L. H. Butterfield et al., “p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma,” Cancer Research, vol. 59, no. 17, pp. 4369–4374, 1999.
- P. Chène, “Inhibiting the p53-MDM2 interaction: an important target for cancer therapy,” Nature Reviews Cancer, vol. 3, no. 2, pp. 102–109, 2003.
- A. Singhal, M. Jayaraman, D. N. Dhanasekaran, and V. Kohli, “Molecular and serum markers in hepatocellular carcinoma: predictive tools for prognosis and recurrence,” Critical Reviews in Oncology/Hematology, vol. 82, no. 2, pp. 116–140, 2012.
- A. Okumura, P. M. Pitha, and R. N. Harty, “ISG15 inhibits Ebola VP40 VLP budding in an L-domain-dependent manner by blocking Nedd4 ligase activity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 10, pp. 3974–3979, 2008.
- M. Liu, X.-L. Xiao-Ling, and B. A. Hassel, “Proteasomes modulate conjugation to the ubiquitin-like protein, ISG15,” The Journal of Biological Chemistry, vol. 278, no. 3, pp. 1594–1602, 2003.
- D. Murphy, K. M. Detjen, M. Welzel, B. Wiedenmann, and S. Rosewicz, “Interferon-α delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases,” Hepatology, vol. 33, no. 2, pp. 346–356, 2001.
- W.-Z. Wu, H.-C. Sun, Y.-Q. Gao et al., “Reduction in p48-ISGFgamma levels confers resistance to interferon-alpha2a in MHCC97 cells,” Oncology, vol. 67, no. 5-6, pp. 428–440, 2004.
- B. Damdinsuren, H. Nagano, H. Wada et al., “Interferon alpha receptors are important for antiproliferative effect of interferon-α against human hepatocellular carcinoma cells,” Hepatology Research, vol. 37, no. 1, pp. 77–83, 2007.
- N. Wong, K. Y.-Y. Chan, P. F. Macgregor et al., “Transcriptional profiling identifies gene expression changes associated with IFN-α tolerance in hepatitis C-related hepatocellular carcinoma cells,” Clinical Cancer Research, vol. 11, no. 3, pp. 1319–1326, 2005.
- T. Noda, H. Nagano, I. Takemasa et al., “Activation of WntΒ-catenin signalling pathway induces chemoresistance to interferon-α5-fluorouracil combination therapy for hepatocellular carcinoma,” British Journal of Cancer, vol. 100, no. 10, pp. 1647–1658, 2009.
- H. Y. Yim, Y. Yang, J. S. Lim, M. S. Lee, D. E. Zhang, and K. I. Kim, “The mitochondrial pathway and reactive oxygen species are critical contributors to interferon-α/β-mediated apoptosis in Ubp43-deficient hematopoietic cells,” Biochemical and Biophysical Research Communications, vol. 423, pp. 436–440, 2012.
- A. Catic, E. Fiebiger, G. A. Korbel, D. Blom, P. J. Galardy, and H. L. Ploegh, “Screen for ISG15-crossreactive deubiquitinases,” PLoS ONE, vol. 2, no. 7, article e679, 2007.
- V. Chau, J. W. Tobias, A. Bachmair et al., “A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein,” Science, vol. 243, no. 4898, pp. 1576–1583, 1989.
- S. Sigismund, S. Polo, and P. P. Di Fiore, “Signaling through monoubiquitination,” Current Topics in Microbiology and Immunology, vol. 286, pp. 149–185, 2004.
- D. Michael and M. Oren, “The p53-Mdm2 module and the ubiquitin system,” Seminars in Cancer Biology, vol. 13, no. 1, pp. 49–58, 2003.
- P. Brazhnik and K. W. Kohn, “HAUSP-regulated switch from auto- to p53 ubiquitination by Mdm2 (in silico discovery),” Mathematical Biosciences, vol. 210, no. 1, pp. 60–77, 2007.
- V. Yadav, S. Sultana, J. Yadav, and N. Saini, “Gatifloxacin induces S and G2-phase cell cycle arrest in pancreatic cancer cells via p21/p27/p53,” PLoS One, vol. 7, Article ID e47796, 2012.